Ablation of TRPM5 in Mice Results in Reduced Body Weight Gain and Improved Glucose Tolerance and Protects from Excessive Consumption of Sweet Palatable Food when Fed High Caloric Diets

• Marie H. Larsson ,

  * E-mail: Marie.h.larsson@astrazeneca.com

  Affiliations Department of Bioscience, Cardiovascular & Metabolic Disease Innovative Medicines, AstraZeneca R&D, Mölndal, Sweden, Department of Discovery Safety, Drug Safety and Metabolism, AstraZeneca R&D, Mölndal, Sweden

  ⨯
• Pernilla Håkansson,

  Affiliation Department of Bioscience, Cardiovascular & Metabolic Disease Innovative Medicines, AstraZeneca R&D, Mölndal, Sweden

  ⨯
• Frank P. Jansen,

  Affiliations Department of Bioscience, Cardiovascular & Metabolic Disease Innovative Medicines, AstraZeneca R&D, Mölndal, Sweden, Department of Screening Sciences & Compound Management, Discovery Sciences, AstraZeneca R&D, Mölndal, Sweden

  ⨯
• Kerstin Magnell,

  Affiliation Department of Reagents and Assay Development, Transgenics, Discovery Sciences, AstraZeneca R&D, Mölndal, Sweden

  ⨯
• Peter Brodin

  Affiliation Department of Bioscience, Cardiovascular & Metabolic Disease Innovative Medicines, AstraZeneca R&D, Mölndal, Sweden

  ⨯